Synapse - Works

Results (5611)

TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Meeting Abstract

Sequist, L. V.; Lee, J. S.; Han, J. Y.; Su, W. C.; Yang, J. C. H.; Yu, H.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Initial results from the phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors

Meeting Abstract

Schram, A.; Spreafico, A.; Oliva, M.; Brana, I.; Garralda, E.; Lakhani, N.; Von Hoff, D.; Borazanci, E.; Pandya, N.; Hoffman, K.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Prospective clinical sequencing distinguishes independent primary cancers from recurrent or metastatic disease

Meeting Abstract

Schram, A. M.; Bandlamudi, C.; Zehir, A.; Ladanyi, M.; Berger, M. F.; Taylor, B. S.; Hyman, D. M.
Cancer Research (2019)

Fulltext@MSK | Save

Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)

Meeting Abstract

Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Moreb, J.; Blade, J.; Hassoun, H.; Cavo, M.; Alegre, A.; Mazumder, A.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Gluthathione peroxidase 2 downregulation in the PyMT mammary tumor model leads to an aggressive phenotype due to stimulation of angiogenesis and tumor stemness via HIF1 alpha signaling

Meeting Abstract

Ren, Z.; Liang, H.; Benard, O.; Suyama, K.; Albanese, J. M.; Norton, L.; Zheng, W.; Hazan, R. B.
Cancer Research (2019)

Fulltext@MSK | Save

First-in-human phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

Meeting Abstract

Sanborn, R. E.; Gabrail, N. Y.; Bhardwaj, N.; Gordon, M. S.; O'Hara, M.; Khalil, D.; Hawthorne, T.; Gedrich, R.; Vitale, L.; Rogalski, M.; more...
Cancer Research (2019)

Fulltext@MSK | Save

A phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer

Meeting Abstract

Reckamp, K. L.; Akerley, W.; Edelman, M. J.; Halmos, B.; He, K.; Johnson, M.; Mudad, R.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the phase Ib TATTON study

Meeting Abstract

Ramalingam, S. S.; Saka, H.; Ahn, M. J.; Yu, H.; Horn, L.; Hida, T.; Cantarini, M.; Verheijen, R.; Wessen, J.; Oxnard, G.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Identification of gene signatures associated with response in a phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Meeting Abstract

Ordentlich, P.; Wang, L.; Tamang, D.; Sullivan, A. H.; Church, S. E.; Rozelle, D.; Meyers, M. L.; Ramalingam, S. S.; Hellmann, M. D.
Cancer Research (2019)

Fulltext@MSK | Save

Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial

Meeting Abstract

Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
Cancer Research (2019)

Fulltext@MSK | Save